NYSE : GKOS

Glaukos Corporation

$166.72 USD

-$1.8 (-1.07%)

Volume
821.99K
Average Volume
1.02M
Market Capitalization
$9.83B
P/E Ratio
-51.30
Dividend Yield
0.00%
Price Target
$192.50
Year High
$184.00
Year Low
$73.16
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.04
Company Overview

NYSE

Thomas William Burns

Medical - Devices

Healthcare

GKOS

1094

US

USD

https://www.glaukos.com

949 367 9600

377322102

0001192448

Liquidity Metrics

0.15

5.04

4.46

1.12

0.00

Sales & Valuation

$507.44M

16.05

14.27

-806.31

-0.21

Profitability

-$3.28

-$187.69M

-30.68%

-31.47%

-27.07%

-20.43%

P/E Metrics

-51.30

0.46

0.46

Analyst Price Target & Rating

$192.50

$215.00

$150.00

Strong Sell

1/5

25 Analysts

-13.39%

Financial Health Scores

23.84

3/9

$413.45M

$920.52M

$238.04M

-$187.93M

Key Metrics (TTM)

$9.82B

16.03

-64.78

5.04

-27.07%

-9.59%

-1.93%

-0.12%

197 days

Company Executives
Name Title
Joseph E. Gilliam President & Chief Operating Officer
Tomas Navratil Chief Development Officer
Jane E. Rady Senior Vice President of Corporate Strategy & Business Development
Tracy Founds Senior Vice President of Global Quality & Medical Safety
L. Jay Katz FACS Chief Medical Officer
Alex R. Thurman Senior Vice President & Chief Financial Officer
Christopher William Lewis Vice President of Investor Relations & Corporate Affairs
Thomas William Burns Chairman & Chief Executive Officer
Michele Allegretto Senior Vice President of Human Resources
Robert L. Davis Senior Vice President, General Counsel & Business Development
Diana A. Scherer Vice President of Compliance & Deputy General Counsel
Poll Results

No votes yet today — be the first to share your view!

About Glaukos Corporation (NYSE:GKOS) Stock

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sal ... es organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

2026-07-30 12:56:07

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

Glaukos Q2 Earnings Call Highlights

2026-07-30 00:05:25

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations.

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say

2026-07-29 23:31:03

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

2026-07-29 21:53:13

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

2026-07-29 19:26:23

Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago.

Glaukos Announces Second Quarter 2026 Financial Results

2026-07-29 16:05:00

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record ne.

Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release

2026-07-28 13:33:59

Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of the Q2 earnings release. Strong revenue growth—41%+ in Q1 and 38% YoY in Q3—has driven recent upgrades and fueled a 91% stock rally since last year. Key catalysts include potential Q2 revenue outperformance, guidance hikes above $640 million, and robust uptake of Epioxa and iDose TR.

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

2026-07-27 07:00:00

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel.

Frequently Asked Questions

What is the current Glaukos Corporation (GKOS) stock price?

Glaukos Corporation(NYSE:GKOS) stock price is $166.72 in the last trading session. During the trading session, GKOS stock reached the peak price of $184 while $73.16 was the lowest point it dropped to. The percentage change in GKOS stock occurred in the recent session was --1.07% while the dollar amount for the price change in GKOS stock was -$1.8.

GKOS's industry and sector of operation?

The NYSE listed GKOS is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of GKOS?

Joseph E. Gilliam | President & Chief Operating Officer
Tomas Navratil | Chief Development Officer
Jane E. Rady | Senior Vice President of Corporate Strategy & Business Development
Tracy Founds | Senior Vice President of Global Quality & Medical Safety
L. Jay Katz FACS | Chief Medical Officer

How many employees does GKOS have?

Number of GKOS employees currently stands at 1094. GKOS operates from One Glaukos Way, Aliso Viejo, CA 92672, US.

Link for GKOS official website?

Official Website of GKOS is: https://www.glaukos.com

How do I contact GKOS?

GKOS could be contacted at phone #949 367 9600 and can also be accessed through its website. GKOS operates from One Glaukos Way, Aliso Viejo, CA 92672, US.

How many shares of GKOS are traded daily?

The average number of GKOS shares traded daily for last 3 months was 1.02M.

What is the market cap of GKOS currently?

The market value of GKOS currently stands at $9.83B with its latest stock price at $166.72